{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T13:31:48Z","timestamp":1769520708060,"version":"3.49.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2018,7,18]],"date-time":"2018-07-18T00:00:00Z","timestamp":1531872000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1007\/s12094-018-1921-5","type":"journal-article","created":{"date-parts":[[2018,7,18]],"date-time":"2018-07-18T22:47:39Z","timestamp":1531954059000},"page":"314-323","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Effectiveness, safety and cost of abiraterone acetate in patients with metastatic castration-resistant prostate cancer: a real-world data analysis"],"prefix":"10.1007","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8849-3732","authenticated-orcid":false,"given":"M.","family":"Koninckx","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. L.","family":"Marco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. T.","family":"Faus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Alcolea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,7,18]]},"reference":[{"key":"1921_CR1","unstructured":"Eurostat. Main statistical findings of prostate cancer. In: Cancer statistics-specific cancers. 2017. \n                    http:\/\/ec.europa.eu\/eurostat\/statistics-explained\/index.php\/Cancer_statistics_-_specific_cancers\n                    \n                  . Accessed 23 Apr 2018."},{"key":"1921_CR2","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1016\/j.eururo.2016.08.002","volume":"71","author":"P Cornford","year":"2017","unstructured":"Cornford P, Bellmunt J, Bolla M, Briers E, De Santis M, Gross T, et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer. Eur Urol. 2017;71:630\u201342.","journal-title":"Eur Urol"},{"key":"1921_CR3","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1056\/NEJMoa040720","volume":"351","author":"IF Tannock","year":"2004","unstructured":"Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502\u201312.","journal-title":"N Engl J Med"},{"key":"1921_CR4","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1016\/S1470-2045(12)70379-0","volume":"13","author":"K Fizazi","year":"2012","unstructured":"Fizazi K, Scher HI, Molina A, Logothetis CJ, Chi KN, Jones RJ, et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2012;13:983\u201392.","journal-title":"Lancet Oncol."},{"key":"1921_CR5","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/S1470-2045(14)71205-7","volume":"16","author":"CJ Ryan","year":"2015","unstructured":"Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PF, Sternberg CN, et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2015;16:152\u201360.","journal-title":"Lancet Oncol."},{"key":"1921_CR6","unstructured":"Conselleria de Sanitat i Salut P\u00fablica. Instrucci\u00f3n 14\/2017 de la Secretar\u00eda Auton\u00f3mica de Salud P\u00fablica y del Sistema Sanitario P\u00fablico de declaraci\u00f3n como MAISE de abiraterona, enzalutamica, cabazitaxel y Dicloruro de Radio 223 en c\u00e1ncer de ulticen met\u00e1stasico resistente a castraci\u00f3n. 2017. \n                    http:\/\/www.san.gva.es\/documents\/152919\/7062676\/Instrucci%C3%B3%2014_2017+C%C3%A0ncer+de+pr%C3%B2stata.pdf\n                    \n                   of subordinate document. Accessed 23 Apr 2018."},{"key":"1921_CR7","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1186\/s12885-015-1257-2","volume":"15","author":"N Hou\u00e9d\u00e9","year":"2015","unstructured":"Hou\u00e9d\u00e9 N, Beuzeboc P, Gourgou S, Tosi D, Moise L, Gravis G, et al. Abiraterone acetate in patients with metastatic castration-resistant prostate cancer: long term outcome of the Temporary Authorization for Use programme in France. BMC Cancer. 2015;15:222.","journal-title":"BMC Cancer."},{"key":"1921_CR8","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s12894-016-0132-z","volume":"16","author":"DM Poon","year":"2016","unstructured":"Poon DM, Chan K, Lee SH, Chan TW, Sze H, Lee EK, et al. Abiraterone acetate in metastatic castration-resistant prostate cancer\u2014the unanticipated real-world clinical experience. BMC Urol. 2016;16:12.","journal-title":"BMC Urol."},{"key":"1921_CR9","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1186\/s12885-017-3755-x","volume":"17","author":"L Cindolo","year":"2017","unstructured":"Cindolo L, Natoli C, De Nunzio C, De Tursi M, Valeriani M, Giacinti S, et al. Safety and efficacy of abiraterone acetate in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: an Italian multicentre \u201creal life\u201d study. BMC Cancer. 2017;17:753.","journal-title":"BMC Cancer."},{"key":"1921_CR10","doi-asserted-by":"publisher","DOI":"10.1177\/1758834017745819","author":"A Cavo","year":"2018","unstructured":"Cavo A, Rubagotti A, Zanardi E, Fabbroni C, Zinoli L, Di Meglio A, et al. Abiraterone acetate and prednisone in the pre- and post-docetaxel setting for metastatic castration-resistant prostate cancer: a mono-institutional experience focused on cardiovascular events and their impact on clinical outcomes. Ther Adv Med Oncol. 2018. \n                    https:\/\/doi.org\/10.1177\/1758834017745819\n                    \n                  .","journal-title":"Ther Adv Med Oncol."},{"key":"1921_CR11","doi-asserted-by":"publisher","first-page":"777","DOI":"10.3111\/13696998.2016.1173042","volume":"19","author":"D Pilon","year":"2016","unstructured":"Pilon D, Queener M, Lefebvre P, Ellis LA. Cost per median overall survival month associated with abiraterone acetate and enzalutamide for treatment of patients with metastatic castration-resistant prostate cancer. J Med Econ. 2016;19:777\u201384.","journal-title":"J Med Econ."},{"key":"1921_CR12","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.ajur.2016.11.005","volume":"4","author":"ME Pollard","year":"2017","unstructured":"Pollard ME, Moskowitz AJ, Diefenbach MA, Hall SJ. Cost-effectiveness analysis of treatments for metastatic castration resistant prostate cancer. Asian J Urol. 2017;4:37\u201343.","journal-title":"Asian J Urol."},{"key":"1921_CR13","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1200\/JCO.2007.12.4487","volume":"26","author":"HI Scher","year":"2008","unstructured":"Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol. 2008;26:1148\u201359.","journal-title":"J Clin Oncol"},{"key":"1921_CR14","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228\u201347.","journal-title":"Eur J Cancer"},{"key":"1921_CR15","unstructured":"US Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. 2009. \n                    https:\/\/www.eortc.be\/services\/doc\/ctc\/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf\n                    \n                   of subordinate document. Accessed 24 Apr 2018."},{"key":"1921_CR16","doi-asserted-by":"publisher","first-page":"3695","DOI":"10.1200\/JCO.2011.35.8648","volume":"29","author":"HI Scher","year":"2011","unstructured":"Scher HI, Morris MJ, Basch E, Heller G. End points and outcomes in castration-resistant prostate cancer: from clinical trials to clinical practice. J Clin Oncol. 2011;29:3695\u2013704.","journal-title":"J Clin Oncol"},{"key":"1921_CR17","doi-asserted-by":"publisher","first-page":"64","DOI":"10.5306\/wjco.v6.i4.64","volume":"6","author":"R Shameem","year":"2015","unstructured":"Shameem R, Hamid MS, Xu KY, Wu S. Comparative analysis of the effectiveness of abiraterone before and after docetaxel in patients with metastatic castration-resistant prostate cancer. World J Clin Oncol. 2015;6:64\u201372.","journal-title":"World J Clin Oncol."},{"key":"1921_CR18","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1177\/1758834017698644","volume":"9","author":"ED Crawford","year":"2017","unstructured":"Crawford ED, Shore ND, Petrylak DP, Higano CS, Ryan CJ. Abiraterone acetate and prednisone in chemotherapy-na\u00efve prostate cancer patients: rationale, evidence and clinical utility. Ther Adv Med Oncol. 2017;9:319\u201333.","journal-title":"Ther Adv Med Oncol."},{"key":"1921_CR19","doi-asserted-by":"publisher","first-page":"39","DOI":"10.2147\/CMAR.S39318","volume":"6","author":"EA Mostaghel","year":"2014","unstructured":"Mostaghel EA. Abiraterone in the treatment of metastatic castration-resistant prostate cancer. Cancer Manag Res. 2014;6:39\u201351.","journal-title":"Cancer Manag Res."},{"key":"1921_CR20","unstructured":"National Comprehensive Cancer Network. Prostate cancer, clinical practice guidelines in oncology. 2018; 2nd version. \n                    https:\/\/www.nccn.org\/professionals\/physician_gls\/recently_updated.aspx\n                    \n                  . Accessed 9 May 2018."},{"key":"1921_CR21","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.urolonc.2016.02.013","volume":"34","author":"A Thortzen","year":"2016","unstructured":"Thortzen A, Thim S, R\u00f8der MA, Brasso K. A single-center experience with abiraterone as treatment for metastatic castration-resistant prostate cancer. Urol Oncol. 2016;34:291.","journal-title":"Urol Oncol."},{"key":"1921_CR22","doi-asserted-by":"publisher","first-page":"265","DOI":"10.9778\/cmajo.20160082","volume":"5","author":"J Rocha","year":"2017","unstructured":"Rocha J, Aprikian AG, Vanhuyse M, Cury FL, Hu J, Pr\u00e9vost N, et al. Impact of abiraterone acetate with and without prior docetaxel chemotherapy on the survival of patients with metastatic castration-resistant prostate cancer: a population-based study. CMAJ Open. 2017;5:265\u201372.","journal-title":"CMAJ Open."},{"key":"1921_CR23","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.eururo.2014.01.030","volume":"67","author":"AA Azad","year":"2015","unstructured":"Azad AA, Eigl BJ, Leibowitz-Amit R, Lester R, Kollmannsberger C, Murray N, et al. Outcomes with abiraterone acetate in metastatic castration-resistant prostate cancer patients who have poor performance status. Eur Urol. 2015;67:441\u20137.","journal-title":"Eur Urol"},{"key":"1921_CR24","doi-asserted-by":"publisher","first-page":"286","DOI":"10.3109\/21681805.2016.1172254","volume":"50","author":"J Svensson","year":"2016","unstructured":"Svensson J, Andersson E, Persson U, Edekling T, Ovanfors A, Ahlgren G. Value of treatment in clinical trials versus the real world: the case of abiraterone acetate (Zytiga) for postchemotherapy metastatic castration-resistant prostate cancer patients in Sweden. Scand J Urol. 2016;50:286\u201391.","journal-title":"Scand J Urol."},{"key":"1921_CR25","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1056\/NEJMoa1704174","volume":"377","author":"K Fizazi","year":"2017","unstructured":"Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med. 2017;377:352\u201360.","journal-title":"N Engl J Med"},{"key":"1921_CR26","doi-asserted-by":"publisher","first-page":"385","DOI":"10.2165\/00002018-200629050-00003","volume":"29","author":"L Hazell","year":"2006","unstructured":"Hazell L, Shakir SA. Under-reporting of adverse drug reactions: a systematic review. Drug Saf. 2006;29:385\u201396.","journal-title":"Drug Saf"},{"key":"1921_CR27","first-page":"296","volume":"10","author":"AS Behl","year":"2017","unstructured":"Behl AS, Ellis LA, Pilon D, Xiao Y, Lefebvre P. Medication adherence, treatment patterns, and dose reduction in patients with metastatic castration-resistant prostate cancer receiving abiraterone acetate or enzalutamide. Am Health Drug Benefits. 2017;10:296\u2013303.","journal-title":"Am Health Drug Benefits."},{"key":"1921_CR28","first-page":"163","volume":"22","author":"CN Bui","year":"2016","unstructured":"Bui CN, O\u2019Day K, Flanders S, Oestreicher N, Francis P, Posta L, et al. Budget impact of enzalutamide for chemotherapy-na\u00efve metastatic castration-resistant prostate cancer. J Manag Care Spec Pharm. 2016;22:163\u201370.","journal-title":"J Manag Care Spec Pharm."}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12094-018-1921-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-018-1921-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-018-1921-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,9]],"date-time":"2019-09-09T11:07:12Z","timestamp":1568027232000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12094-018-1921-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,18]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["1921"],"URL":"https:\/\/doi.org\/10.1007\/s12094-018-1921-5","relation":{},"ISSN":["1699-048X","1699-3055"],"issn-type":[{"value":"1699-048X","type":"print"},{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,18]]},"assertion":[{"value":"4 June 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"For this type of study formal consent is not required.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}